{{Rsnum
|rsid=11881222
|Gene=IL28B
|Chromosome=19
|position=39244283
|Orientation=plus
|GMAF=0.2576
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=IFNL3
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 52.3 | 33.8 | 13.8
| HCB | 93.3 | 6.7 | 0.0
| JPT | 79.5 | 20.5 | 0.0
| YRI | 44.4 | 41.3 | 14.3
| ASW | 0.0 | 0.0 | 0.0
| CHB | 93.3 | 6.7 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}
{{PMID Auto
|PMID=19749757
|Title=Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
}}

{{PharmGKB
|RSID=rs11881222
|Name_s=
|Gene_s=IL28B
|Feature=
|Evidence=PubMed ID:19749757
|Annotation=Phenotype: This variant is associated with null virological response (NVR) in Janapese patients with hepatitis C virus infection treated with PEG-INF-alpha plus ribavirin. Study size: Initial sample:154; Replication Sample: 172. Study population/ethnicity: Japanese. Significance metric(s): P=2.84 x 10(-31) (NVR). Type of association: GN; CO
|Drugs=interferon alfa-2a, recombinant; ribavirin
|Drug Classes=
|Diseases=Hepatitis C; Hepatitis C, Chronic
|Curation Level=Curated
|PharmGKB Accession ID=PA165260381
}}
{{PMID Auto
|PMID=21070502
|Title=Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort
}}

{{PMID Auto
|PMID=20887330
|Title=High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients.
}}

{{PMID Auto
|PMID=21389156
|Title=The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11881222
|overall_frequency_n=40
|overall_frequency_d=128
|overall_frequency=0.3125
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=37
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23866096
|Title=The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients
}}

{{PMID Auto
|PMID=24621321
|Title=Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-alpha-2a with ribavirin therapy: a case report
|OA=1
}}

{{PMID Auto
|PMID=23103287
|Title=IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus.
}}

{{PMID Auto
|PMID=23135173
|Title=Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}